- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02528695
Adipose Tissue Imaging in Type 2 Diabetes (ATI-DM2)
Adipose Tissue Imaging in Patients With Type 2 Diabetes, Pilot Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Type 2 diabetes has become a worldwide epidemic with a prevalence of approximately 700,000 patients and an annual incidence of 70,000 in the Netherlands. The development of T2D depends on both genetic and nutritional factors and is characterized by insufficient insulin secretion by the pancreatic beta-cells and insulin resistance in liver, skeletal muscle and white adipose tissue. Insulin resistance often precedes beta-cell loss and is associated with central obesity, high blood pressure, hyperinsulinemia and dyslipidemia, all of which may lead to microvascular and cardiovascular complications.
White adipose tissue is increasingly considered a key metabolic organ in the development of insulin resistance. Especially the distribution of adipose tissue in the body is important. Indeed, visceral adipose tissue is a risk factor for coronary heart disease, certain cancers and T2D and associated with an increased cardiovascular and all-cause mortality, whereas excess of subcutaneous adipose tissue is not. There are distinct differences in the functional and hormonal characteristics of VAT and SAT, which may explain part of the mechanisms underlying the development of insulin resistance.
A more complete understanding of the molecular mechanisms that lead to T2D will enable the identification of individuals at highest risk, which could lead to more targeted prevention and pharmacological therapy.
FDG PET/CT is an established tomographic technique to image glucose metabolism with validated applications in oncology, infectious and inflammatory diseases, brain metabolism and cardiac viability. Several studies exploring the usefulness of FDG PET in imaging glucose metabolism in white adipose tissue reported lower overall glucose uptake in obese than in lean subjects. In both subject groups, glucose uptake was higher in VAT than in SAT. Glucose uptake in VAT and SAT was inversely related to insulin resistance, but uptake in GFAT was not. There are only few studies analyzing glucose uptake in patients with T2D with FDG PET/CT. In one study the impact of abdominal obesity and newly diagnosed T2D on insulin action in adipose tissue was evaluated, suggesting an excess of SAT to provide a sink for glucose, and thereby resulting in a compensatory decrease in insulin resistance. More research is needed to demonstrate the differences in glucose uptake in various adipose tissue depots in patients with T2D and correlate it with insulin resistance.
In order to keep glucose at a constant level during the FDG PET examination, usually a hyperinsulinemic euglycaemic glucose clamp is performed before scanning. Recently, a case-report was published describing an FDG PET/CT during an iatrogenic hypoglycemic state in a non-diabetic patient, which demonstrated remarkably increased glucose uptake in VAT and SAT. Based on this observation we hypothesize that glucose uptake during a hypoglycaemic state will be more pronounced in various adipose tissue depots. To our knowledge, this has not been performed in healthy volunteers or in patients with T2D. A controlled hypoglycemic state may be achieved by a hyperinsulinemic hypoglycaemic clamp, which has been used in several clinical studies. A demonstration of differences in FDG uptake in white adipose tissue between healthy volunteers and T2D patients and between VAT, SAT and GFAT under hypoglycaemic conditions would provide more insight in the glucose metabolism of adipose tissue and contribute to our understanding of insulin resistance in T2D. Even more importantly, this imaging technique might help to better characterise patients with T2D or patients at risk to develop T2D, and may thereby help to increase our understanding of the pathophysiology of T2D and the metabolic syndrome, which could lead to more targeted prevention in patients at risk and to personalised pharmacological therapy after the onset of clinically overt disease.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Gelderland
-
Nijmegen, Gelderland, Netherlands, 6500HB
- Radboudumc
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age > 18 years
- BMI 27-40
For healthy volunteers:
- Fasting blood glucose < 6.1 mmol/L
- HbA1c < 42 mmol/mol (6%)
For T2D patients:
- Clinical overt Type 2 Diabetes
- on a glucose-lowering diet or on oral glucose-lowering medication
- T2D stable and under control for minimal 2 years
- HbA1c < 75 mmol/mol (9%)
Exclusion Criteria:
- Renal dysfunction
- Overt symptomatic neuropathy or proliferative retinopathy
- A history of cardiovascular disease complications (myocardial infarction, stroke, peripheral artery disease)
- Pregnancy or lactating
- Using subcutaneous insulin
- Incapability to provide informed consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Healthy euglycemic clamp
In 5 healthy volunteers an 18F-FDG PET/CT will be performed during an euglycemic clamp
|
18F-FDG PET/CT
euglycemic clamp
|
Active Comparator: healthy hypoglycemic clamp
In 5 healthy volunteers an 18F-FDG PET/CT will be performed during a hypoglycemic clamp
|
18F-FDG PET/CT
hypoglycemic clamp
|
Experimental: Type 2 diabetes hypoglycemic clamp
In 5 type 2 diabetes patients, an 18F-FDG PET/CT will be performed during a hypoglycemic clamp
|
18F-FDG PET/CT
hypoglycemic clamp
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Glucose uptake in adipose tissue measured by uptake of 18F-FDG on PET images
Time Frame: 1 year
|
1 year
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- NL44098.091.13
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus Type 2
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
AstraZenecaRecruiting
-
Daewoong Pharmaceutical Co. LTD.Not yet recruitingT2DM (Type 2 Diabetes Mellitus)
-
Zhongda HospitalRecruitingType 2 Diabetes Mellitus (T2DM)China
Clinical Trials on 18F-FDG PET/CT
-
National Cancer Institute (NCI)CompletedNeurofibromatosis | MPNSTUnited States
-
Peking Union Medical College HospitalActive, not recruitingHepatocellular Carcinoma | Bile Duct CancerChina
-
Central Hospital, Nancy, FranceNot yet recruiting
-
Peking UniversityUnknownNeuroendocrine TumorsChina
-
Peking University Cancer Hospital & InstituteUnknownLymphoma | Positron-Emission Tomography | Tumor, SolidChina
-
Ohio State University Comprehensive Cancer CenterCompletedUnspecified Adult Solid Tumor, Protocol SpecificUnited States
-
University of Lausanne HospitalsGeorge Coukos, MD PhD, Head of oncologyRecruiting
-
Harbin Medical UniversityUnknown
-
British Columbia Cancer AgencyRecruitingProstatic Neoplasms | Prostate Cancer | Neuroendocrine Tumors | Neuroblastoma | Carcinoid Tumor | ParagangliomaCanada
-
Washington University School of MedicineTerminatedCervical Cancer | Uterine Cervical Neoplasms | Uterine Cervical CancerUnited States